Contact The Gross Law Firm by March 10, 2025 Deadline to Join Class Action Against BioAge Labs, Inc.(BIOA)

1. BioAge Labs faces a class-action lawsuit regarding its IPO disclosures. 2. Safety concerns led to discontinuation of a critical drug trial in December 2024. 3. BIOA's stock dropped sharply from $20.09 to $4.65 following the trial announcement. 4. Shareholders from the IPO period are encouraged to register for potential recovery. 5. The lawsuit highlights issues of misleading information about drug safety.

Legal

85

4m saved

Insight

Article

FAQ

Why Very Bearish?

The class-action lawsuit indicates serious governance issues reminiscent of past cases like Valeant Pharmaceuticals, which faced severe stock declines due to litigation and compliance failures.

How important is it?

The article addresses a significant legal issue affecting BIOA's stock due to the implications of the lawsuit and its potential for financial recovery.

Why Long Term?

Ongoing litigation can harm BIOA's reputation and investor confidence, potentially leading to long-lasting price pressure.

Related Companies

BIOA

NOTICE TO SHAREHOLDERS OF BIOAGE LABS, INC.

NEW YORK, Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).

Shareholder Information

Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE: https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=127272&from=4

CLASS PERIOD

This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge's registration statement for the initial public offering held on or about September 26, 2024.

ALLEGATIONS

According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs. Following this news, BioAge's stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.

DEADLINE

March 10, 2025. Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=127272&from=4

NEXT STEPS FOR SHAREHOLDERS

Once you register as a shareholder who purchased shares of BIOA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 10, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM?

The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903

SOURCE

The Gross Law Firm